• 1. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 2. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 3. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 4. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 5. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Thiamines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Thiamines

Research Brief on Ethyl Thiamine (CAS: 3505-34-8): Recent Advances and Applications in Chemical Biology and Medicine

Ethyl Thiamine (CAS: 3505-34-8), a derivative of thiamine (vitamin B1), has garnered significant attention in recent years due to its potential applications in chemical biology and medicine. This research brief aims to synthesize the latest findings on Ethyl Thiamine, focusing on its chemical properties, biological activities, and therapeutic potential. The compound's unique structural modifications, compared to its parent molecule, offer enhanced stability and bioavailability, making it a promising candidate for various biomedical applications.

Recent studies have explored the role of Ethyl Thiamine in metabolic pathways, particularly in the context of thiamine-dependent enzymatic reactions. Thiamine pyrophosphate (TPP), the active form of thiamine, is a cofactor for several key enzymes involved in carbohydrate metabolism. Ethyl Thiamine has been shown to efficiently convert to TPP in vivo, suggesting its utility in addressing thiamine deficiency disorders. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that Ethyl Thiamine exhibits superior pharmacokinetic profiles compared to conventional thiamine supplements, with faster absorption rates and prolonged half-life in animal models.

In addition to its metabolic roles, Ethyl Thiamine has been investigated for its neuroprotective properties. Research published in Neurochemical Research (2024) highlighted its ability to mitigate oxidative stress and inflammation in neuronal cells, potentially offering therapeutic benefits for neurodegenerative diseases such as Alzheimer's and Parkinson's. The study utilized advanced imaging techniques to track the compound's distribution in brain tissues, revealing its ability to cross the blood-brain barrier effectively. These findings underscore the compound's potential as a novel neuroprotective agent.

Another area of interest is the application of Ethyl Thiamine in cancer therapy. A 2024 preprint from BioRxiv reported that Ethyl Thiamine derivatives can selectively target cancer cells by disrupting their energy metabolism. The study employed high-throughput screening to identify Ethyl Thiamine analogs with enhanced anti-proliferative effects against glioblastoma cells. These analogs were found to inhibit the activity of transketolase, a TPP-dependent enzyme critical for the pentose phosphate pathway in cancer cells. This targeted approach could pave the way for developing more effective and less toxic anticancer therapies.

From a chemical synthesis perspective, recent advancements have focused on optimizing the production of Ethyl Thiamine to improve yield and purity. A 2023 paper in Organic Process Research & Development detailed a novel catalytic method for the ethylation of thiamine, reducing the reliance on hazardous reagents and minimizing byproduct formation. This environmentally friendly synthesis route aligns with the growing demand for sustainable pharmaceutical manufacturing practices.

In conclusion, Ethyl Thiamine (CAS: 3505-34-8) represents a versatile and promising compound in the realm of chemical biology and medicine. Its enhanced bioavailability, neuroprotective effects, and potential in cancer therapy highlight its multifaceted applications. Future research should focus on clinical trials to validate its efficacy and safety in humans, as well as further exploration of its mechanistic pathways. The ongoing development of synthetic methodologies will also play a crucial role in scaling up production for therapeutic use.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)